Other OTC - Delayed Quote USD

Fagron NV (ARSUF)

18.59

0.00

(0.00%)

At close: March 22 at 1:04 PM EDT

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial statements and the

GlobeNewswire 7 days ago

ARSUF
0.00%
Record revenue of €209 million in first quarter reflecting 15% topline growth

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024. Key Highlights Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regionsOrganic growth at CER of 12.3%

GlobeNewswire 8 days ago

ARSUF
0.00%
Disclosure notification from Mawer Investment Management Ltd.

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 March 2024 – 6PM CET Disclosure notification from Mawer Investment Management Ltd. On 18 March 2024, Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Mawer Investment Management Ltd. that its shareholding crossed the 5% disclosure threshold as the result of the acquisition of voting securities or voting rights on 15 March 2024. N

GlobeNewswire last month

ARSUF
0.00%
Fagron publishes annual report 2023

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron publishes annual report 2023 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2023. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 13 May 2024. The annual report is available in the official Dutch version and in English translatio

GlobeNewswire last month

ARSUF
0.00%
Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 15 February 2024 – 7AM CET Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023 Fagron, the leading global player in pharmaceutical compounding today publishes its full year results for the period ending 31 December 2023. Key Highlights Strong topline performance with 11.6% reported revenue growth (12.5% at CER) and 10.5% organic revenue growth at CER supported

GlobeNewswire 2 months ago

ARSUF
0.00%
Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 8 January 2024 – 8AM CET Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold On 27 December 2023, Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from AOC Pharma S.à r.l., an entity controlled by the value investor Active Ownership, that its shareholding crossed the 10% disclosure threshold as the result of the acqu

GlobeNewswire 3 months ago

ARSUF
0.00%
Disclosure of notification received from BNP Paribas Asset Management SA

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 December 2023 – 6PM CET Disclosure of notification received from BNP Paribas Asset Management SA Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from BNP Paribas Asset Management SA. Notification of BNP Paribas Asset Management SA On 8 December 2023, Fagron received a notification that the shareholding of BNP Paribas Asset Management

GlobeNewswire 4 months ago

ARSUF
0.00%
Continued strong third quarter performance with 11% topline growth to €191 million

Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 October 2023 – 7:00 AM CET Continued strong third quarter performance with 11% topline growth to €191 million Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2023. Key Highlights Solid revenue growth continues with 10.6% reported growth (13.9% at CER) and 10.2% organic growth (13.4% at CER) to €191.4 millionSustained

GlobeNewswire 6 months ago

ARSUF
0.00%
Fagron completes share buy-back program

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 September 2023 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period, from 18 September 2023 through 19 September 2023, Fagron purchased 17,266 of its owns shares at an average price of €16.12 per share corresponding to a total amount of €277,612.81. A total of 138,372 Fagron shares have been repurchased under the buy-back program at an averag

GlobeNewswire 6 months ago

ARSUF
0.00%
Progress share buy-back program Fagron

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 15 September 2023 – 6PM CET Progress share buy-back program Fagron In the period from 11 September 2023 through 15 September 2023, Fagron purchased 27,000 of its owns shares at an average price of €16.81 per share corresponding to a total amount of €453,745.66. These purchases are part of the share buy-back program of up to 138,372 Fagron shares to fulfill Fagron’s obligations under its long term incentive scheme, which was ann

GlobeNewswire 7 months ago

ARSUF
0.00%
Fagron delivers strong performance with 13% topline growth and 14% increase in REBITDA for first half of 2023

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 August 2023 – 7AM CET Fagron delivers strong performance with 13% topline growth and 14% increase in REBITDA for first half of 2023 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2023. Key Highlights Strong topline performance with 13.1% reported revenue growth (12.1% at CER) and 8.4% organic revenue growth at CEROrganic

GlobeNewswire 8 months ago

ARSUF
0.00%
Fagron shareholders approve majority voting items

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 8 May 2023 – 7 PM CET Fagron shareholders approve majority voting items Today, Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders. The meeting approved the voting items, with the exemption of the proposal to approve the accelerated vesting in case of a public offer on or a change of control over Fagron as provided for in the Performance Share Plan (agenda item 10). T

GlobeNewswire 11 months ago

ARSUF
0.00%
Fagron increases share capital through exercise subscription rights

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 May 2023 – 8:00 AM CET Fagron increases share capital through exercise subscription rights Fagron, the leading global player in pharmaceutical compounding, announces that as a result of the exercise of subscription rights, 236,250 new shares have been issued on 2 May 2023. These newly issued shares are entitled to dividend as of financial year 2022. In accordance with the Belgian transparency legislation, Fagron notes that it

GlobeNewswire 11 months ago

ARSUF
0.00%

Performance Overview

Return	ARSUF	BEL 20
YTD	+0.60%	+3.24%
1-Year	+0.60%	-0.09%
3-Year	-14.48%	-3.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fagron NV (ARSUF)

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

Record revenue of €209 million in first quarter reflecting 15% topline growth

Disclosure notification from Mawer Investment Management Ltd.

Fagron publishes annual report 2023

Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023

Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold

Disclosure of notification received from BNP Paribas Asset Management SA

Continued strong third quarter performance with 11% topline growth to €191 million

Fagron completes share buy-back program

Progress share buy-back program Fagron

Fagron delivers strong performance with 13% topline growth and 14% increase in REBITDA for first half of 2023

Fagron shareholders approve majority voting items

Fagron increases share capital through exercise subscription rights

Performance Overview